Just one month into 2025, a handful of stocks have already generated some massive gains. Top 2025 performers include several ...

We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...

Unsurprisingly, Akero owes this incredible one-day gain to data from a midstage clinical trial. Akero Therapeutics is ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...

Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...

Analyst David Lebowitz of Citi maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $65.00.Invest ...

In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...

What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing ...

Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...